Skip to main content

Mirum Pharmaceuticals Inc(MIRM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Latest News

United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023
Associated Press - Mon Dec 18, 2023
Associated Press
Mon Dec 18, 2023
Stocks that traded heavily or had substantial price changes on Monday: United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall
Why Shares of Travere Therapeutics Are Slumping Thursday
Motley Fool - Thu Sep 21, 2023
Motley Fool
Thu Sep 21, 2023
A mixed trial could hurt a kidney drug's chances of full approval.
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Business Wire - Thu May 4, 2023
Business Wire
Thu May 4, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
Business Wire - Thu Apr 27, 2023
Business Wire
Thu Apr 27, 2023
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first quarter 2023 financial results and recent...
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering
Business Wire - Wed Apr 12, 2023
Business Wire
Wed Apr 12, 2023
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional...
American Airlines, Emerson Electric fall; Triton, Chart rise
Associated Press - Wed Apr 12, 2023
Associated Press
Wed Apr 12, 2023
Stocks that traded heavily or had substantial price changes Wednesday: American Airlines, Emerson Electric fall; Triton, Chart rise
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Business Wire - Wed Apr 12, 2023
Business Wire
Wed Apr 12, 2023
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering...
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
Business Wire - Wed Apr 12, 2023
Business Wire
Wed Apr 12, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Mon Apr 10, 2023
Business Wire
Mon Apr 10, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,950 shares of common...
Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors
Business Wire - Thu Apr 6, 2023
Business Wire
Thu Apr 6, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Tim Walbert has been appointed to the company’s Board of Directors. In addition to Mr. Walbert’s appointment, the company shared that Niall O’Donnell, Ph.D., a Mirum director since...
Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis
Business Wire - Wed Apr 5, 2023
Business Wire
Wed Apr 5, 2023
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced submission to the European Medicines Agency (EMA) of a variation application to the Marketing Authorization for LIVMARLI ® (maralixibat) oral solution, to extend the label for progressive...
Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
Business Wire - Tue Mar 14, 2023
Business Wire
Tue Mar 14, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a reduction in age from one year to three months for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Fri Mar 10, 2023
Business Wire
Fri Mar 10, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,050 shares of common...
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
Business Wire - Wed Mar 8, 2023
Business Wire
Wed Mar 8, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update.
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023
Business Wire - Wed Mar 1, 2023
Business Wire
Wed Mar 1, 2023
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023. Mirum will also host a conference call to discuss the fourth quarter and year-end 2022...
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
Business Wire - Tue Feb 14, 2023
Business Wire
Tue Feb 14, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has submitted a supplemental New Drug Application (sNDA) for LIVMARLI ® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients two months of age and...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Fri Feb 10, 2023
Business Wire
Fri Feb 10, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,000 shares of common...
Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
Business Wire - Thu Feb 9, 2023
Business Wire
Thu Feb 9, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Tue Jan 10, 2023
Business Wire
Tue Jan 10, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,900 shares of common...
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
Business Wire - Mon Jan 9, 2023
Business Wire
Mon Jan 9, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided a preview of the company’s plans, estimated revenue and net product sales for Q4 and full year 2022 ahead of its presentation at the 41 st Annual J.P. Morgan Healthcare Conference.
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Business Wire - Tue Jan 3, 2023
Business Wire
Tue Jan 3, 2023
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will...
Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors
Business Wire - Mon Dec 19, 2022
Business Wire
Mon Dec 19, 2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee. Dr. Cardon brings nearly 30 years...
Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
Business Wire - Tue Dec 13, 2022
Business Wire
Tue Dec 13, 2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the European Commission has granted marketing authorization for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Fri Dec 9, 2022
Business Wire
Fri Dec 9, 2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 9, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,200 shares of common...
Mirum Pharmaceuticals Provides Development Program Updates
Business Wire - Tue Nov 29, 2022
Business Wire
Tue Nov 29, 2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility. ICP is a setting of cholestasis during pregnancy...